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Abstract
– The incidence of recurrence of nephrotic syndrome/
focal segmental glomerulosclerosis (NS/FSGS) is
variable (~30%)
– The incidence of recurrence is less in African-Ameri-
cans than in whites and Hispanics
– Graft survival rates are decreased in recipients with
FSGS, especially if remission of the NS is not achieved
in those with recurrence
– Although controversial, the use of living donor (LD)
transplants are not contraindicated; however, obligato-
ry heterozygote parental grafts with a podocin mutation
should be used with caution
– Optimal treatment to induce a remission post-transplant
has not been delineated
– Pre-transplant and/or prophylactic post-transplant pre-
operative plasmapheresis (PP) for high-risk patients—
especially those with recurrence in a previous graft—
may be promising
– An international multicenter controlled study is re-
quired to delineate the optimal approach to prevent
and/or treat the recurrence of NS/FSGS
Keywords Recurrentfocalsegmentalglomerulosclerosis
(FSGS).Plasmapheresis.Nephrectomy.
Immunosuppressivemedications.Long-termoutcome
Introduction
Focal segmental glomerulosclerosis (FSGS) is a histologic
(pathologic) diagnosis that encompasses numerous specific
clinical entities with potential varied etiologies. Steroid-
resistant nephrotic syndrome (SRNS) is a specific clinical
phenomenon that may vary histologically from minimal
change nephrotic syndrome (MCNS) to FSGS, but it also
may be associated with other specific histological
diagnoses.
The most frequently acquired disease resulting in end-
stage renal disease (ESRD) in children is FSGS, accounting
for 8.3% of the chronic renal insufficiency (CRI) patients,
14.3% of the dialysis patients, and 11.4% of the transplant
recipients included in the North American Pediatric Renal
Transplant Cooperative Study (NAPRTCS) registry [1].
In 1972, Hoyer et al. [2] from Minnesota described the
recurrence of NS in 3/4 pediatric renal allograft recipients
whose original disease was FSGS. At post-mortem exam-
ination, the lesion of FSGS was present in the grafts of two
recipients [2]. An editorial accompanying the publication of
this article in Lancet stated that “renal transplantation may
be contraindicated (in patients with FSGS) leaving dialysis
as probably the only means of prolonging life” [3].
The purpose of this teaching review article will be to
address the factors that influence the incidence of recur-
rence of NS/FSGS in renal allografts, establish the known
risk factors for recurrence, and delineate the current
preventive and therapeutic approaches to the recurrence of
NS/FSGS in pediatric renal allograft recipients.
What is the incidence of recurrence of post-transplant
NS/FSGS?
The general consensus is that 30–40% of recipients whose
original disease was NS/FSGS will clinically manifest
recurrence [4]. In most instances, recurrence is clinically
apparent in the immediate post-transplant period, frequently
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e-mail: richard.fine@stonybrook.eduwith substantive proteinuria in the initial 24 hours following
transplantation. However, the onset of clinical recurrence
has been reported to occur at more than one year following
transplantation. The delay in initial clinical manifestations
may be coincident to the occurrence of acute tubular
necrosis (ATN), which occurs more frequently in live donor
(LD) and deceased donor (DD) recipients with FSGS [5]. It
has been proposed that the “immediate fulminate recur-
rence of NS/FSGS post-transplant likely predisposes such
grafts to ATN and explains the increased incidence of ATN
in this patient population [5].
What is the incidence of subsequent recurrence in a patient
who manifested clinical recurrence in a previous graft?
Re-transplantation of a recipient with recurrence of NS/
FSGS in a previous graft has been associated with a ~80%
recurrence rate [4]. Recently, a 100% recurrence rate has
been reported in ten recipients of a second (6), third (3),
and fourth (1) transplant [6]. Therefore, proceeding with a
subsequent transplant in a patient who manifested previous
recurrence has been discouraged. Recently, pre-operative
plasmapheresis (PP) was successful in preventing clinical
recurrence in 3/6 patients whose initial graft was lost in
association with clinical recurrence [7].
What is the incidence of recurrence in recipients
with mutations of genes that encode for podocin?
The association of mutations impacting on the structure of
the foot processes in the region of the slit diaphragm of the
glomerular basement membrane in patients with sporadic
and familial NS has potentially delineated the pathophys-
iology of the NS in such patients [8]. Initial publications
indicated that the incidence of recurrence of NS/FSGS in
patients with podocin mutations was similar to that reported
for all patients with NS/FSGS [9]. However, a recent
analysis of 73 patients with either homozygous/compound
heterozygous (65) or heterozygous (8) mutations revealed a
7.7% incidence in the former and a 62.5% incidence in the
latter recipients [10]. If these data are confirmed, it would
seem advantageous to test all potential recipients with
ESRD secondary to NS/FSGS for such mutations in order
to delineate an optimal transplant strategy.
Do patients with the glomerular tip lesion who receive
a renal allograft manifest recurrence of the NS?
Howie et al. [11] reported that 12 of 14 recipients whose
native kidney manifested the glomerular tip lesion had
clinical recurrence of the NS post-transplant. In all 12
recipients, the glomerular tip lesion was the only histologic
abnormality on graft biopsy. These data support the concept
that the glomerular tip lesion may be the earliest histologic
abnormality in the NS/FSGS spectrum of disease. Precise
incidence and outcome data await subsequent reports.
Does race impact on the recurrence of NS/FSGS?
Although the disease process appears more virulent in
African-American (AA) children with NS/FSGS [12], it is
interesting that the incidence of recurrence following
transplantation in this ethnic population is decreased. At
least three studies [5, 13, 14] have shown that the incidence
of recurrence in the AA recipient was <50% of that in the
Caucasian recipient. Hispanic recipients had an incidence
similar to that of Caucasians. The precise reason for this
disparity in incidence has not been delineated.
Has the incidence of recurrence changed
with the introduction of new immunosuppressive regimens?
Since the initial publication in 1972 of Hoyer et al. [2],
there has been a significant change in the available
immunosuppressive agents and regimens to both prevent
and treat rejections. Despite these regimens, which have
substantially reduced the incidence of acute rejection
episodes and markedly improved short-term allograft
survival rates, the incidence of recurrent NS/FSGS has
remained unaffected [14]. Bartosh et al. [14] reviewed the
NAPRTCS database for the period 1998–2003 and found
the incidence of recurrence was 31%, which was similar to
the incidence in the initial NAPRTCS report for the period
1987–1990 [4].
What are the risk factors for the recurrence
of NS/FSGS?
Three factors identified in the 1970s to be associated as risk
factors for recurrence were: (1) the rapid progression to
ESRD in a period of <3 years; (2) the presence of
mesangial hypercellularity on biopsy; and (3) the age at
onset of the clinical NS of >6 years. More recently, the
presence of a circulating permeability factor [15], the use of
induction therapy in the immunosuppressive regimen [16],
and native kidney nephrectomy either prior to or at the time
of transplantation [17] have been reported to be associated
with an increased risk of recurrence.
Does the presence of an identified circulating factor
predispose to the recurrence of NS/FSGS?
Savin et al. [15] showed that the presence of a permeability
factor (Palb) with an activity of ≥0.50 was associated with
a recurrence rate of 86% (6/7), whereas an activity of <0.50
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Plasmapheresis was associatedw i t hb o t har e d u c t i o ni nt h e
Palb activity and in urinary protein excretion.
Is induction therapy a risk factor for the recurrence
of NS/FSGS?
Raafat et al. [16] noted a recurrence rate of NS/FSGS of
43% between 1968 and 1997. However, it was only 11%
(1/9) in those who did not receive induction, whereas it was
53% (15/28) in those receiving some form of antilympho-
cyte serum (ALS). Conversely, Gagnodoux [17] reported
an incidence of recurrence of 31% prior to 1985 when no
induction therapy with antilymphocyte globulin/antithymo-
cyte globulin (ALG/ATG) was used compared to 30%
following the introduction of induction therapy. Both Sheth
et al. [18] and Hubsch et al. [19] noted a significant
increase in the incidence of recurrence (17.6% vs 37.5%
and 38% vs 83%, respectively) with the use of anti-IL2
receptor antibody as induction therapy. In the most recent
analysis of NAPRTCS for the period 1998–2003, Bartosh
et al. [14] noted an overall incidence of recurrence of 31%
(51/165), which was similar to no induction (30%) or the
use of polyclonal antibody (27%) or monoclonal antibody
(33%). Therefore, advocating the restriction of induction
therapy to reduce the incidence of recurrence awaits the
performance of a multicenter prospective randomized
controlled study.
Is native nephrectomy a risk factor for the recurrence
of NS/FSGS?
Analysis of the recent NAPRTCS database [14] indicated a
significant (p<0.001) difference in the incidence of
recurrence in recipients who had undergone prior native
kidney nephrectomy (50%) compared to those whose
native kidneys were not removed prior to or at the time of
transplantation (22%). A possible explanation for this
phenomenon was that the native kidneys provided a
“sponge” for any circulating putative antibody and that
native nephrectomy facilitated a sufficient level of circula-
tion of such antibodies which were deposited in the graft
precipitating recurrence. Other reports [20] have come to
the same conclusion.
Does the recurrence of NS/FSGS impact on the allograft
survival rate?
Baum et al. [21] in 2002 and Bartosh et al. [14] in 2004
reviewed the NAPRTCS database, which indicated inferior
long-term graft survival rates in both recipients of LD and
DD grafts whose original disease was FSGS. Analysis of
the UNOS database demonstrated a similar disadvanta-
geous graft survival rate for recipients whose original
disease was FSGS compared to recipients with other
primary renal diseases [22].
A consensus is that 50% of the grafts with the recurrence
of NS/FSGS are lost, presumably as a result of the recurrent
pathologic process. However, data from Schachter and
Harmon [23] noted that long-term survival rates signifi-
cantly (p=0.002) improved in those recipients with
recurrence who achieved remission with some therapeutic
intervention compared to those who failed to go into
remission and had persistent NS.
Does age at the time of transplantation impact on graft
survival in recipients with FSGS?
Adolescent recipients (13–17 years of age) with FSGS
have a significantly poorer graft survival rate with both LR
and DD grafts compared to younger recipients (0–12 years
of age) [21]. In actuality, the 0–12 year-old recipient DD
graft survival rate was similar in the FSGS and no FSGS
groups. The specific reason for this phenomenon is not
known. However, Scientific Registry of Transplant Recip-
ients (SRTR) data have consistently demonstrated that
adolescent recipients have substantially poorer long-term
graft survival rates, which approach that of recipients
>65 years of age at transplantation [24].
Should an LD graft be utilized in children with ESRD
secondary to FSGS?
At least five reports from 1989 to 1999 [4, 25–28]
concluded that recipients with FSGS had a greater risk of
allograft failure from an LD graft than from a DD graft. A
precise reason for this phenomenon was not delineated.
In 2001, Baum et al. [5] reviewed the NAPRTCS
database and showed that the 5-year LD graft survival rate
was 69% for recipients with FSGS compared to 82% with
no FSGS (p<0.001), whereas it was 60% and 67%,
respectively, in the DD groups. The authors concluded that
the long-term advantage of LD grafts was lost in recipients
with FSGS.
Conversely, Huang et al. [22] proffered that, although
the LD advantage was not observed in AA pediatric
recipients, the authors recommend that LD transplantation
be considered for all racial groups with FSGS.
With this potential excellent outcome with newer
preventative and therapeutic regimens for recurrence to be
detailed subsequently, the previous concerns regarding the
use of an LD graft may not be appropriate. However, the
recurrence of NS/FSGS in two recipients with a homozy-
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obligatory heterozygote mother indicates that the obligatory
heterozygote parental donor may not be ideal [29, 30].
Similarly, the development of FSGS and ESRD in three
donors [28, 31] at some point following donation also
indicates that appropriate informed consent should be
obtained prior to utilizing an LD graft in recipients with
FSGS.
What are the therapeutic options available to produce
a remission following the recurrence of NS in recipients
with FSGS?
In 1988, Laufer et al. [32] reported the remission of NS in
two pediatric recipients following nine sessions of PP at 3
and 6 months post-transplant. Both recipients manifested
prolonged ATN. This led to the general use of PP in
patients with recurrence. However, no randomized control
trial was ever performed and the rate of remission has been
variable.
Ingulli et al. [33] in 1990 reported the success in
inducing a remission with high-dose cyclosporine in three
pediatric recipients. The rationale for the increased dosage
was that hyperlipidemia bound the cyclosporine and higher
doses were required to achieve adequate bioavailability.
The precise dose and length of treatment with the “high-
dose” regimen were never delineated in a controlled trial.
However, this report led to the general approach of using a
higher maintenance dosage of cyclosporine once a remis-
sion was obtained.
Recently, Raafat et al. [34] reported a recurrence rate of
67% (16/24) in recipients with FSGS between 1991 and
2003. The oral dose of cyclosporine was increased to
24 mg/kg/day until either remission was achieved or renal
toxicity was evident. Complete remission was achieved in
69% (11/16) within 14 days to 19 months (10/11 within
3 months) and 12% (2/16) had a partial remission.
Concomitant PP was administered to 7/16 recipients with
recurrence.
Cochat et al. [35] in 1993 introduced a regimen of PP
and cyclophosphamide in three patients who remitted
within 12–24 days. This regimen has been adopted by
some centers, especially for patients who failed to remit
with PP alone. However, again, no controlled trial has been
performed.
Plasma protein absorption was introduced by Dantal
et al. [36] in 1994 for recipients with an identified
circulating factor. Although proteineuria was reduced in
the eight patients treated, it was permanent in only one
patient following discontinuation of the procedure.
Subsequent reports utilizing this technique in pediatric
recipients are limited.
Recently, Salomon et al. [37] reported an 82% (14/17)
remission rate utilizing IV Cyclosporine at 3 mg/kg/day to
reach a cyclosporine level of 250–350 mg/dl. These data
add to the potential utility of high-dose cyclosporine in
inducing a remission following the recurrence of NS/FSGS.
With the use of angiotensin-converting enzyme/angio-
tensin receptor blocker (ACE/ARB) therapy to reduce
proteinuria in patients with various forms of renal disease,
it would seem logical to extend the use of these agents to
recipients with the recurrence of NS/FSGS. However,
there has been no controlled study of the use of these
drugs either alone or as adjunctive to other therapeutic
regimens.
Can pre-operative PP reduce the risk of recurrence
of NS/FSGS?
Ohta et al. [38] in 2001 reported the recurrence of NS/
FSGS in 9/21 grafts. Pre-operative PP was performed in 15
and recurrence developed in five, whereas 4/6 without pre-
operative PP developed recurrence. The authors concluded
that pre-operative PP was effective in preventing the
recurrence of NS/FSGS.
At the International Pediatric Transplant Association
(IPTA) Congress in August 2005, Rainthavorn et al. [39]
from the UCLA reported a recurrence rate of 100% in three
recipients of DD grafts who received one session of pre-
operative PP, whereas it was 57% (4/7) in recipients of LD
grafts who received <5 pre-operative PP and 0% in three
recipients who received >5 pre-transplant PP sessions. The
authors concluded that >5 pre-operative PP sessions
prevented the recurrence of NS/FSGS.
Kawamura et al. [40], at the same IPTA congress,
reported a recurrence rate of 15.4% (2/13) in LD recipients
who received 1–2 pre-operative PP sessions, as well as
native kidney nephrectomy. Recurrence was evident at
6 days and 8 months post-transplant, respectively, and
remitted with post-transplant PP.
A recent publication involving primarily adult recipients
(9/10 were adult) utilized a combination of pre- and post-
operative PP in high-risk patients—six with recurrence in a
prior graft and four with rapid progression to ESRD
(<3 years) [7]. The LD recipients received eight courses
of PP over a two-week period—one week prior to and one
week following transplantation. The DD recipients initiated
PP within 24 hours of transplantation and continued for
two weeks post-transplant. There was no recurrence in the
four recipients with rapid progression to ESRD and 3/6
recipients with a recurrence in a prior graft had no
recurrence.
Certainly, the utilization of pre-operative and prophy-
lactic post-operative PP appears promising in high-risk
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delineate the optimal preventative and therapeutic
approaches.
Conclusions
The incidence of recurrence of nephrotic syndrome/focal
segmental glomerulosclerosis (NS/FSGS) has remained at
~30% for the past four decades, despite the introduction
of newer and more potent immunosuppressive regimens.
Multiple risk factors have been identified to predispose or
precipitate clinical recurrence. However, no prospective
multicenter studies have validated the relationships.
Mutations of the gene encoding for podocin may identify
a population of patients with NS/FSGS who are at a
lower risk for clinical recurrence. Because of the potential
for an increased incidence of recurrence and/or graft loss,
living donor (LD) grafts should be used with constraint.
Graft survival rates in recipients with NS/FSGS are
decreased. However, if a remission can be induced, the
outlook for long-term graft survival is substantially
improved.
Various therapeutic regimens, including pre-operative
plasmapheresis (PP), high-dose cyclosporine, IV cyclo-
sporine, and adjunctive cyclophosphamide, have proven
to be effective. However, there have been no multi-
center controlled studies to delineate the optimal thera-
peutic approach. Recent use of pre-operative and/or
post-operative prophylactic PP to prevent the recurrence
of NS/FSGS is exciting. Controlled trials are required
to validate efficacy and delineate a precise preventative
regimen.
Questions
(Answers appear following the references)
1. The incidence of recurrence of FSGS is:
a. Comparable in whites and African-Americans
b. Less in whites than Hispanics
c. Less with re-transplants than with primary grafts
d. Not influenced by pre-transplant plasmapheresis
e. Between 30% and 40%
2. The use of a deceased donor is mandatory in a patient
with FSGS when:
a. A living donor graft is not available
b. The initial graft was lost as a result of recurrence
c. The parental donor is not an obligatory podocin
heterozygote
d. The potential live-donor is a haplotype mismatch
e. The potential live-donor is a B-antigen mismatch
3. Graft survival following the recurrence of NS in a
patient with FSGS is dependent upon:
a. A reduction in the magnitude of proteinuria to
3.0 g/kg/day
b. The lack of histologic evidence of FSGS during the
initial post-transplant month
c. Inducing a complete remission of the NS
d. The immediate use of post-transplant plasmapheresis
e. The use of a one haplotype-matched live-related
donor
4. The optimal approach to prevent the recurrence of NS
in patients with FSGS:
a. Includes cyclophosphamide and plasmapheresis
b. Includes one week of pre-transplant plasmapheresis
c. Includes post-operative tacrolimus and plasmapheresis
d. Includes post-operative sirolimus and plasmapheresis
e. Has not been delineated
5. The recurrence of NS in patients with congenital
nephrotic syndrome:
a. Has not been reported with the “Finnish” type
b. Is >80% in recipients with diffuse mesangial
sclerosis
c. Is uniform with Fin-major/Fin-minor genotype
d. Is associated with the development of antinephrin
antibodies
e. Is associated with anti-podocin antibodies
6. Which of the following does not impact on the
recurrence of NS in patients with FSGS:
a. Race
b. Native kidney nephrectomy
c. Recurrence in a prior graft
d. Podocin mutation
e. None of the above
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